Do Statins Cause Muscle Pain? What the Trials Actually Found

Do Statins Cause Muscle Pain? What the Trials Actually Found

A physician reviews a lab results printout with a middle-aged male patient seated on an exam table, his hand resting on his calf, in a sunlit clinic room

Stopping a statin the morning new muscle pain shows up feels like the responsible thing to do. Most of the time, the pill is not what caused the pain.

Call him Ray. He is a composite, built from several men I have treated in San Antonio over two decades, not one person in my chart. Fifty-seven. A cardiologist started him on a statin after a coronary calcium score came back higher than either of them wanted. Two weeks in, his calves ached on the stairs. He read enough overnight to be frightened of rhabdomyolysis, a word he had never heard before that week, and stopped the pill the next morning without calling anyone.

He was not wrong to take the pain seriously. He was wrong about the odds, and nobody had given him the real ones. He also treated the six weeks off the statin as free. They were not. A high calcium score means plaque already sitting in the artery wall, and a statin is one of the few things proven to slow it down.

Here is what four controlled trials, not forum threads, actually found.

The gap between what patients report and what statins cause starts with how the question gets asked. A 2018 systematic review in the Journal of Cachexia, Sarcopenia and Muscle looked at five trials that tested the same patients under both open-label and blinded conditions. Muscle symptoms were reported by 15 to 20 percent of statin users in ordinary observational studies, where patients and doctors both know which drug is being taken. In blinded, placebo-controlled trials, the rate drops to 3 to 5 percent. The authors call the gap the “drucebo effect,” and across the five trials it accounted for 38 to 78 percent of the muscle symptoms blamed on the drug. Expecting pain, it turns out, is one of the more reliable ways to produce it.

The cleanest demonstration of that came from a trial built around one problem: patients like Ray who had already quit. The SAMSON trial, published in the New England Journal of Medicine in 2020, recruited 60 people who had stopped a statin because of side effects, then gave each of them a year of alternating months on the statin, on an identical placebo, and on nothing at all, in random order, without telling them which was which. Mean symptom intensity was 8.0 during the no-pill months. It was 15.4 on placebo. It was 16.3 on the actual statin. Placebo and drug were statistically indistinguishable. Ninety percent of the symptom burden patients blamed on the statin showed up just as reliably on a sugar pill. When the researchers showed participants their own data, side by side, half of them went back on the statin.

A second, larger trial reached the same place by a different door. StatinWISE ran 200 patients through a series of n-of-1 trials, each person cycling through statin and placebo months and rating their own muscle symptoms along the way. The result: no meaningful difference between the two, a mean difference of -0.11 on their symptom scale, with a confidence interval that straddled zero. Not a trend toward harm. Nothing.

None of this means statin muscle injury is fiction. It means it is rare, and the rare cases look nothing like Ray’s calf soreness. Real statin-induced muscle damage, confirmed by a blood test called creatine kinase, shows up as actual weakness, often with dark or cola-colored urine from muscle breakdown spilling into the bloodstream. A 2004 FDA-based analysis in JAMA, built from more than 250,000 patients, put the rate of hospitalized rhabdomyolysis from the three most commonly prescribed statins, used alone, at 0.44 cases per 10,000 person-years. That is not zero. It is also not the fear that drives most people to quit on their own at week two.

So what do you actually do with new muscle pain on a statin.

Dark urine, real weakness, or pain severe enough to change how you walk is not a wait-and-see symptom. Stop the drug and call your doctor the same day, and ask for a creatine kinase level before deciding anything else. If it’s after hours or the office is closed, go to urgent care or the emergency room instead of waiting for a callback. That is the one scenario where quitting first and asking questions later is the right order.

Ordinary soreness, the kind Ray had, deserves a different approach than guessing. A structured trial off the drug and back on it, with your doctor tracking symptoms both times, is essentially what SAMSON did for its participants one patient at a time. It takes a few weeks in each direction to get a real answer instead of an impression formed in the first bad week. Sometimes switching to a different statin or a different dosing schedule resolves it even when the pain was real. Coenzyme Q10 gets mentioned often online as a fix; the trial evidence for it is mixed at best, and I don’t prescribe around a supplement with that little behind it.

If someone genuinely cannot tolerate any statin after a fair trial, there are non-statin options, and I want to be honest about what they cost in both directions. Ezetimibe is cheap and well tolerated but a weaker LDL-lowering tool on its own. PCSK9 inhibitors work well and cost considerably more, with insurance approval that can take weeks of paperwork before the first dose. Neither is a casual substitute, and I don’t reach for either before confirming the statin itself is the actual problem, not the fear of it.

What decides whether any of this matters is the number underneath the symptom, not the symptom alone. A standard lipid panel misses the two markers that usually explain why a statin was prescribed in the first place, and most routine lab work stops well short of what’s needed to know whether the person in front of me actually needs the drug, needs a different one, or needs something else entirely. That is the question I start with, before the one about muscle pain. It’s the same approach I use for most symptoms that show up after a new prescription: find out what’s true before anyone decides what to feel afraid of.

Ray came back in six weeks after he’d quit. We ran four weeks off, four weeks back on, and tracked his calves both times. They hurt on the stairs either way, statin or not, almost exactly the same amount. He is back on the medication. His coronary calcium score is still the number that matters, and now he knows the ache in his calves isn’t the number that was ever going to move it.

Dr. Shiv Kumar Goel, MD is an internal medicine physician and the founder of Prime Vitality Care in San Antonio, Texas, with over two decades in hospital medicine.


Dr. Shiv Goel, smiling in a professional gray suit with a black tie and pocket square, embodying expertise in integrative medicine and wellness.

About Dr. Shiv Kumar Goel, MD

Dr. Shiv Kumar Goel, MD is an internal medicine physician and the founder of Prime Vitality Care in San Antonio, Texas, with over two decades in hospital medicine. He writes at healingthesplit.com about the gap between what medicine measures and what patients feel.

November 17, 2026

5 min read

Functional Medicine, Wellness & Longevity


Related Articles

Ready to Optimize Your Health?

Schedule a consultation with our expert team at Prime Vitality Care and discover personalized solutions for hormone optimization, weight management, and aesthetic treatments.

Book Your Consultation
Two ways in. Apply Book Studio (210) 876-1635